ATAI Life Sciences N.V. reported that on October 16, 2025, it entered an underwriting agreement to publicly offer 23,725,000 common shares at $5.48 each, aiming to raise approximately $121.2 million for clinical development and general corporate purposes. As of September 30, 2025, they had around $114.6 million in cash and investments.